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Abstract 
This study further explores the association between schizophrenia and caffeine use by 
combining two prior published Spanish samples (250 schizophrenia outpatients and 290 controls 
from the general population) with two Spanish long-term inpatient samples from the same 
hospital (145 with schizophrenia and 64 with other severe mental illnesses). The specific aims 
were to establish whether or not, after controlling for confounders including tobacco smoking, 
the association between schizophrenia and caffeine is consistent across schizophrenia samples 
and across different definitions of caffeine use. The frequency of caffeine use in schizophrenia 
inpatients was not significantly higher than that in non-schizophrenia inpatients (77%, 111/145 
vs. 75%, 48/64) or controls but was significantly higher than in schizophrenia outpatients. The 
frequency of high caffeine users among caffeine users in schizophrenia inpatients was not 
significantly higher than in non-schizophrenia inpatients (45%, 50/111 vs. 52%, 25/48) or 
controls, but was significantly lower than in schizophrenia outpatients. Smoking was 
significantly associated with caffeine use across all samples and definitions.   Between 2-3% of 
schizophrenia inpatients, schizophrenia outpatients and non-schizophrenia inpatients showed 
caffeinism (>700 mg/day in smokers). Several of these smoking patients with caffeinism were 
also taking other inducers, particularly omeprazole. The lack of consistent association between 
schizophrenia and caffeine use is surprising when compared with the very consistent association 
between tobacco smoking and caffeine use across all of our analyses (use and high use in users) 
and all our samples. The confounding effects of tobacco smoking may explain in large part the 
apparent association between schizophrenia and caffeine use.  
Keywords: caffeine; case-control study; drug interactions, omeprazole; schizophrenia; smoking.  
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1. Introduction 
Caffeine probably causes most of its biological effects by blocking all adenosine 
receptors located at the neurons and brain glial cells and removing the brain’s adenosinergic 
tonus (Ribeiro and Sebastião, 2010). Animal models suggest that 1) adenosine plays a role 
opposite to dopamine in the striatum; 2) adenosine agonists produce effects similar to dopamine 
antagonists; and 3) adenosine antagonists, such as caffeine, produce effects similar to increased 
dopaminergic neurotransmission (Ferré, 1997).   
Schneier and Siris (1987) suggested that schizophrenia was associated with increased 
rates of caffeine consumption.  Later, Hughes et al. (1998) described that patients with 
schizophrenia appeared to have high caffeine intake but studies were small and not completely 
consistent. These old studies did not control for the confounding factor that schizophrenia is 
strongly and consistently associated with tobacco smoking (de Leon and Diaz, 2005) and tobacco 
smoking is also associated with caffeine (Istvan and Mattarazzo, 1984; Gurpegui et al., 2007).  
Furthermore, tobacco smoke compounds induce caffeine metabolism by increasing the 
expression of the cytochrome P450 1A2 (CYP1A2).  Heavy smokers need two to three times 
higher caffeine intake to get the same serum caffeine concentrations as non-smokers (de Leon et 
al., 2003). Other CYP1A2 inducers are some antiepileptic drugs (carbamazepine or phenytoin) 
and omeprazole (de Leon et al. 2005). 
In two consecutive studies, Gurpegui et al. (2004; 2006) explored the relationship 
between schizophrenia and caffeine intake after controlling for tobacco smoking. First, current 
caffeine intake was associated with current smoking and alcohol use in 250 schizophrenia 
outpatients (Gurpegui et al., 2004).  Among caffeine consumers, the amount of consumed 
caffeine was associated with smoking but not with schizophrenia symptomatology measured 
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cross-sectionally. In an extension study, the schizophrenia outpatient sample was compared with 
290 controls (Gurpegui et al., 2006).  Current caffeine intake was significantly less frequent in 
schizophrenia after controlling for potential confounding factors.  Among caffeine consumers, 
high caffeine consumption was significantly more frequent in schizophrenia outpatients than in 
the control group.  
In our previous studies we did not pay attention to “caffeinism”, the extremely high 
consumption of caffeine in schizophrenia. The literature only provides anecdotal reports of 
“caffeinism” but Williams and Ghandi (2008) have proposed that caffeine intake >700 mg/day 
may be a sign of this “caffeinism.”   
If animal pharmacological models are correct in proposing a close relationship between 
the adenosine system and dopamine, then one should find a strong and consistent relationship 
between schizophrenia and caffeine in the clinical environment.  The lack of definitive proof of 
an association between caffeine intake and schizophrenia is surprising, since schizophrenia is 
definitively associated with excessive use of nicotine and water. 
There is a strong and consistent association between schizophrenia and tobacco smoking 
(de Leon and Diaz, 2012).  When compared with the general population, schizophrenia patients 
definitively have increased daily smoking initiation and decreased smoking cessation. When 
compared with people with other severe mental illnesses (SMIs), this association is less evident; 
schizophrenia is only associated with a smaller increase of daily smoking initiation but no 
differences in smoking cessation. Vulnerability to schizophrenia may be associated with an 
increased risk for starting daily smoking (de Leon, 1996; de Leon and Diaz, 2012). Wing et al. 
(2012) reviewed the proposed neurobiological mechanisms behind the association between 
smoking and schizophrenia. 
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Polydipsia, an excessive intake of water and other fluids, is associated with schizophrenia 
after controlling for confounders such as smoking, chronicity or medications. This association 
has been demonstrated in institutionalized patients using SMIs as controls (de Leon et al., 1994; 
1996; 2002), but it is less evident in less severe and less chronic patients (de Leon et al., 1994).  
Although schizophrenia appears to be consistently associated with excessive use of 
nicotine and water, it is not clear that it is consistently associated with excessive use of caffeine. 
Moreover, a hepatic pharmacokinetic mechanism may explain why heavy smokers with 
schizophrenia consume more caffeine so that the same quantity of caffeine reaches their brains. 
In the extension study (Gurpegui et al., 2006), we demonstrated two significant associations 
between caffeine and schizophrenia, one negative (fewer caffeine users) and one positive (more 
high-intake users within caffeine users), but we did not compare them with people with other 
SMIs, who are better controls for schizophrenia patients.  
This study further explores the association between schizophrenia and caffeine use by 
combining the two prior published Spanish samples (250 schizophrenia outpatients and 290 
controls) with two additional Spanish samples of long-term inpatients from the same hospital: 
145 with schizophrenia and 64 with other SMIs sharing similar environmental influences 
including psychiatric medications. The specific aims were to establish, after controlling for 
confounders including tobacco smoking, whether or not the association between schizophrenia 
and caffeine is consistent across schizophrenia samples and across different operational 
definitions of caffeine use (using versus not using caffeine, high intake in caffeine users and total 
daily caffeine consumption in caffeine users). 
2. Subjects and methods 
2.2. Subjects  
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 All inpatients from a long-term psychiatric hospital (Hospital Psiquiátrico de Conxo, 
Santiago de Compostela, Spain) were cross-sectionally investigated for the prevalence of caffeine 
intake and its quantity. DSM-IV diagnoses were made by the treating psychiatrist after reviewing all 
medical records available, which include many years of observation (Table 1). There were 111 
schizophrenia inpatients and 48 with other SMIs. Similarly to the outpatient sample, this new 
sample included schizoaffective disorder. The study was approved by an ethics committee and 
patients signed a written informed consent. 
 The previously-published Spanish schizophrenia sample (see footnote g of Table 2) 
included 250 stable outpatients (Gurpegui et al., 2004; 2006). The previously-published 258 
Spanish controls were recruited at a family medicine outpatient clinic (see footnote i of Table 2) 
and appeared to be a reasonable representation of the general population (Gurpegui et al., 2006).  
2.2. Access to caffeine and tobacco  
 There is almost unlimited access to caffeinated beverages and tobacco in this urban hospital. 
The main limiting factor is the money available to each patient from their disability pensions and/or 
family. The hospital cafeteria tends to be cheaper than surrounding businesses and provides 
caffeinated coffee in two sizes and caffeinated colas in three different sizes. Patients can walk to 
surrounding areas and buy caffeinated beverages from shops and/or consume coffee in nearby 
cafeterias. The nursing staff, who has worked with these patients for many years, knows these 
businesses very well, is aware of the interactions between the patients and surrounding community, 
and attempts to keep them as smooth as possible. No patient consumed tea beverages, but this is a 
cultural choice.  
 Nursing staff kept patients’ cigarettes. These cigarettes were bought in large quantities using 
the patients’ and/or family’s money. Patients could also buy more expensive cigarettes in the 
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hospital cafeteria or outside the hospital. In summary, by law, patients are free to smoke as much as 
they desire, but the prohibition against smoking during some hospital activities and the need to ask 
the nursing staff for cigarettes probably contributed to lengthening the time between cigarettes.  
2.3. Procedures 
 As in the prior studies (Gurpegui et al., 2004; 2006), the consumption of caffeinated 
beverages, tobacco, alcohol and illegal drugs was surveyed. Caffeine intake was assessed by 
treating physicians when they considered the patient most likely to cooperate. A standardized 
questionnaire was used to record the number of coffee beverages and caffeinated colas consumed 
per week. It differed from the outpatient questionnaire in three minor ways. First, the inpatient 
questionnaire did not ask about tea since nobody consumed it; second, the questions about the 
size of the beverages were easier to answer since the hospital used standard sizes; and third, 
nurses who had known the patients for years were available to help the psychiatrists make better 
clinical judgments rather than blindly trusting patients’ information. Caffeine intake in mg/day 
was computed by employing previously used correction factors (see footnote e, Table 1). In 
caffeine users, a high amount of caffeine intake was defined as a caffeine intake ≥200 mg/day 
(Gurpegui et al., 2005). Smoking assessments used the same definitions as before (Gurpegui et 
al., 2005; see Table 1, footnote b) and included the Fagerström Test for Nicotine Dependence 
(FTND) (Heatherton et al., 1991) which required the patient to answer some subjective 
questions. To establish the number of cigarettes used daily, the psychiatrist also consulted the 
nursing staff members who controlled most of the cigarettes. The history of alcohol and illegal 
drug abuse or dependence was assessed by treating psychiatrists using all available information. 
Patients could not use alcohol or illegal drugs on hospital grounds. 
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 For the first time, we used the definition of caffeinism as a caffeine intake >700 mg/day 
for smokers (Williams and Ghandi, 2008). As non-smokers have approximately half the caffeine 
metabolic capacity that smokers have (de Leon et al., 2003), a definition of caffeinism in non-
smokers as a caffeine intake >350 mg/day was explored.  
2.4. Statistical analysis 
 Total caffeine intake in mg/day was used as the dependent variable in gamma regression 
models with a log link that analyzed only caffeine users (Table 2). Log-gamma regression 
models were conducted with Stata 13 (StataCorp LP, College Station, TX). They fit well 
according to residual analyses and the link test.  
 The association between schizophrenia and the dichotomous dependent variable, caffeine 
use or no caffeine use, was explored in univariate analyses using ORs with their 95% CI from 
two-way cross-tabulations (footnote a of Table 3). Then a logistic regression model was built by 
starting with the independent variables that provided a significant p-value in univariate analyses 
(Table 3, upper panel).  A similar set of univariate analyses and a logistic regression analysis, 
plus the addition of inducer use as an independent variable, were performed in caffeine 
consumers by using a high amount of caffeine intake (200 mg/day) as the dependent variable 
(Table 4, upper panel). Analogous analyses compared inpatients with schizophrenia versus 
outpatients with schizophrenia, and inpatients with schizophrenia versus controls from the 
general population (Tables 3 and 4, middle and lower panels). Logistic regressions were 
performed with the Statistical Package for the Social Sciences (SPSS 21). All models fit well 
according to the Hosmer-Lemeshow goodness-of-fit test (Hosmer and Lemeshow, 2000).    
3. Results 
3.1. Sample description and daily caffeine intake 
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 Table 1 describes patients and their daily caffeine intake 
3.2. Log-gamma regression in individuals consuming caffeine 
In the inpatient sample, schizophrenia had no significant effects on daily caffeine intake 
(Table 2, footnote e). After adjusting for the number of cigarettes smoked and comparing with 
the general population, schizophrenia was not significantly associated with daily caffeine intake, 
either in schizophrenia inpatients (Table 2, third panel, footnotes j and k) or in schizophrenia 
outpatients (Table 2, fourth panel, footnotes l and m). After controlling for confounders, the 
number of cigarettes smoked was associated with increased caffeine intake in four analyses 
(Table 2, four panels). Taking inducers had a significant effect size in inpatients (42.2%, Table 2, 
upper panel).  
 3.3. Caffeinism 
 In the smokers of the inpatient sample, there were 4 schizophrenia and 1 non-
schizophrenia patients consuming >700 mg/day of caffeine (Table 5). Three of these 5 patients 
were also taking omeprazole, which might contribute to a greater induction and the need for 
higher caffeine doses. In the outpatient schizophrenia sample, there were 7 smokers consuming 
>700 mg/day of caffeine. The caffeinism prevalences were around 3% in all 3 SMI samples and 
0% in the Spanish controls (see Table 5, lower panel and footnote b).  
 Our attempt to explore a definition of caffeinism as consuming >350 mg/day in non-
smoking inpatients indicated that 3 of 4 subjects were probably consuming high quantities of 
caffeine to compensate for omeprazole (Table 5).  
3.4. Comparing prevalences of caffeine use in schizophrenia inpatients vs. inpatients with SMI  
 There was no significant difference between schizophrenic inpatients vs. SMI inpatients 
in the prevalence of caffeine use (77%, 111/145 vs. 75%, 48/64, respectively; Pearson 2=0.06; 
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p=0.81; OR=1.1, CI 0.55-2.2). Significant variables were male sex, current smoking and history 
of alcohol abuse/dependence in the univariate analyses, and male sex and current smoking in the 
logistic regression (Table 3, upper panel).  
3.5. Comparing prevalences of caffeine use in schizophrenia inpatients vs. schizophrenia 
outpatients  
 There was a significant difference between schizophrenia inpatients and schizophrenia 
outpatients in the prevalence of caffeine use (77%, 111/145, versus 59%, 147/250, respectively; 
unadjusted p<0.001). After adjusting for potential confounders, this difference remained 
significant (OR=3.5, p<0.001) and male sex, current smoking and inpatient status were also 
significant (Table 3, middle panel). 
3.6. Comparing prevalences of caffeine use in schizophrenia inpatients vs. controls   
Schizophrenia inpatients (77%, 111/145) did not differ significantly from controls who 
came from the general population (70%, 204/290) in their likelihood of being caffeine consumers 
(unadjusted OR=1.4, p=0.17), not even after adjusting for potential confounders (p=0.57).  
Significant variables in the logistic regression were male sex and current smoking (Table 3, 
lower panel).   
3.7. Comparing prevalences of high caffeine use among caffeine users in schizophrenia 
inpatients vs. inpatients with SMI  
Among patients currently consuming caffeine, a comparison of schizophrenia inpatients 
versus SMI inpatients showed no significant difference in the prevalences of high caffeine intake 
(45%, 50/111 vs. 52%, 25/48, respectively; Pearson 2=0.7; p=0.41; OR=0.75, CI 0.38-1.5). The 
significant variables in the univariate analyses and the logistic regression were current smoking 
and taking inducers (Table 4, upper panel). 
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3.8. Comparing prevalences of high caffeine use among caffeine users in schizophrenia 
inpatients vs. schizophrenia outpatients  
 Schizophrenia inpatients who consumed caffeine were significantly less likely to be high-
level caffeine consumers than schizophrenia outpatients who consumed caffeine (45%, 50/111, 
versus 64%, 94/147, respectively; unadjusted p=0.002). This difference remained significant 
after controlling for potential confounders (adjusted OR=0.47, p=0.004). Male sex and current 
smoking were also significant (Table 4, middle panel). 
3.9. Comparing prevalences of high caffeine use among caffeine users in schizophrenia 
inpatients vs. the general population   
Inpatients with schizophrenia who were caffeine consumers (45%, 50/111) did not  
significantly differ from caffeine consumers from the general population (36%, 73/204) in their 
likelihood of being high-intake caffeine consumers (unadjusted OR=1.47, p=0.11), not even after 
adjusting for current smoking (p=0.9). Only current smoking was significant (Table 4, lower 
panel). 
4. Discussion 
4.1. Lack of consistency in the association between schizophrenia and prevalence of caffeine use  
 The first study aim was to establish the stability of the association of schizophrenia with 
prevalence of caffeine use after controlling for confounders. We found that schizophrenia 
inpatients had no significantly greater frequency of caffeine use than non-schizophrenia 
inpatients or controls from the general population. The schizophrenia inpatient sample had 
significantly greater frequency of caffeine use than the schizophrenia outpatients, who also had 
significantly lower frequency than the controls (Gurpegui et al., 2006).   
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4.2. Lack of consistency in the association between schizophrenia and prevalence of high 
caffeine use among caffeine users  
The second study aim was to establish the stability of the association of schizophrenia 
with high caffeine use among caffeine users after controlling for confounders. We found that 
schizophrenia inpatients had no significantly greater frequency of high caffeine use among 
caffeine users than did non-schizophrenia inpatients or controls from the general population. 
Moreover, schizophrenia inpatients had a significantly lower frequency than schizophrenia 
outpatients after controlling for confounding variables. Our clinical experience suggests that 
average schizophrenia outpatients may have more access to caffeine and tobacco products. Our 
data supported greater daily access to cigarettes and caffeine in outpatient smokers compared to 
inpatient smokers, although access to caffeine by caffeine users was not greater in outpatient 
non-smokers than in inpatient non-smokers (Table 6).   
4.3. Caffeine intake and caffeinism  
Caffeine intake was not associated with schizophrenia when compared with controls or 
other SMI inpatients (Table 2). The limited published information suggests that the extreme use 
of very high levels of caffeine, or caffeinism, may be particularly associated with schizophrenia 
(Williams and Gandhi, 2008; Meredith et al., 2013). Our two surveys indicate that a small 
number of schizophrenia patients (3%) may consistently show caffeinism, defined as >700 
mg/day. Our inpatient survey also identified a patient with caffeinism and psychotic disorder 
NOS and a history of polysubstance abuse.  Several of these patients with caffeinism were taking 
omeprazole, indicating that additive inductive effects of omeprazole with smoking may explain 
some caffeinism cases. Better surveys in the future should measure serum caffeine levels and 
control for medications with inductive effects.  
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4.4. Consistency of the association between tobacco smoking and caffeine use  
 The lack of a consistent association between schizophrenia and caffeine use is surprising 
when compared with the very consistent association between tobacco smoking and caffeine use 
across all of our analyses. After controlling for confounders, current smoking was significantly 
associated with increased prevalence of caffeine use in all three analyses comparing 
schizophrenia inpatients with SMI inpatients, schizophrenia outpatients and controls. Similarly, 
in the three analyses and after controlling for confounders, current smoking was significantly 
associated with increased prevalence of high caffeine use in caffeine users and with higher 
caffeine intake in caffeine users. Therefore, smoking is very strongly and consistently associated 
with caffeine use and high caffeine use, and this association may be an important component of 
the apparent association between schizophrenia and caffeine use.  
4.5. Limitations 
 Although our surveys have greater strengths than prior studies due to the use of relatively 
large samples of systematically recruited patients and careful control of smoking and other 
confounding factors, they are not free of limitations. The samples were studied cross-sectionally 
and not followed longitudinally. Conducting longitudinal studies in schizophrenia and obtaining 
funding for them is not easy. The control sample of inpatients with other SMIs was very 
heterogeneous but reflected the usual pattern of admissions in this Spanish long-term hospital. 
Our experience with US state hospitals is similar (de Leon et al.,1996; 2002). Most of the long-
term inpatients have schizophrenia and those who do not have schizophrenia are a heterogeneous 
patient mix.  
In the inpatient sample, we had no ratings on schizophrenia symptoms or extrapyramidal 
symptoms. However, we have serious doubts that caffeine has a strong association with either 
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schizophrenia or extrapyramidal symptoms. In the outpatient sample, the correlations between 
caffeine intake and PANSS scores, long-term prognosis or daily antipsychotic intake were very 
low <0.10 in both the total sample and in caffeine users. Undoubtedly the schizophrenia 
inpatients included patients with illnesses of much greater chronicity and severity than the 
schizophrenia outpatients. We think that that greater severity and/or chronicity in schizophrenia 
would not influence caffeine intake in any way, but we have to acknowledge that we have no 
way of correcting for that difference.  
This study included only one outpatient schizophrenia sample that had a significantly 
lower prevalence of caffeine use than both the schizophrenia inpatient and general population 
control samples. Therefore, we do not know if that lower prevalence is specific to the 
schizophrenia outpatient sample or whether it can be generalized to other schizophrenia 
outpatient samples. We are convinced that this is not due to lack of access to caffeine (see Table 
6).  
 Omeprazole (and less frequently other antiepileptic inducers) appeared to contribute to 
high caffeine intake in the inpatients but this could not be examined in the outpatient sample. 
The most obvious limitation was the lack of collection of serum caffeine samples to definitively 
establish when there is high caffeine use and to better control for the effects of smoking and 
other inducers in caffeine metabolism. Caffeine has a relatively short half-life. To better establish 
the relationship between caffeine intake and metabolism one can average morning and afternoon 
serum caffeine concentrations (de Leon et al. 2003), or also measure serum concentrations of 
paraxanthine, a longer-lasting metabolite (Perera et al. 2011). The lack of serum caffeine levels 
has to be placed in the context of the very few published studies reporting them in schizophrenia 
patients. In a study of patients trying to quit smoking, Ghandi et al. (2010) found higher serum 
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caffeine levels in 104 smokers with schizophrenia (2722 ng/mL) compared with 63 smokers 
without any mental illness (1122 ng/mL).  
Our schizophrenia outpatients had access to alcohol and demonstrated that alcohol and 
caffeine use were significantly associated. On the other hand, in caffeine users, alcohol was 
associated with less frequent high caffeine consumption among non-smokers, probably because 
alcohol may potentiate caffeine brain pharmacodynamic effects (Gurpegui et al., 2006). Chronic 
alcohol intake decreases adenosine tone (Ferré and O'Brien, 2011), suggesting that alcohol users 
may have decreased need for higher caffeine intake since lower caffeine intake may have the 
same effects in the brain for a chronic alcohol user as high caffeine intake has for a non-alcohol 
user. As our inpatients had no access to alcohol, we could not replicate the possibility of this 
pharmacodynamic interaction between alcohol and caffeine in non-smokers (Gurpegui et al., 
2006).  
In conclusion, the apparent association between schizophrenia and caffeine use is not 
particularly strong or consistent after controlling for confounders or using different controls. In 
particular, this association may be partly explained by confounding with smoking. Schizophrenia 
does not appear to be consistently associated with an increased prevalence of caffeine use and 
the increased prevalence of high caffeine intake in caffeine users does not stand up when 
controlling for confounders. Omeprazole and antiepileptic inducers, and particularly smoking, 
contribute to the excessive caffeine intake in schizophrenia. Future epidemiological studies, 
preferably using serum concentrations, will need to establish whether caffeinism is particularly 
prevalent in schizophrenia or not, and determine the contribution of inducers. 
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Table 1. Description of the sample          
Variables    Schizophrenia inpatients Inpatients with other SMIsa  
PERCENTAGES 
♂ gender     68% (98/145)   69% (44/64) 
Age (>37 years)    90% (130/145)   86% (55/64) 
College education       5% (7/145)     3% (2/64) 
Current smokingb    63% (92/145)   69% (44/64) 
History of alcohol abuse/dependence  19% (28/145)   42% (27/64)  
Taking any inducerc    37% (54/145)   56% (36/64) 
Omeprazole     34% (49/145)   50% (32/64) 
Carbamazepine or phenytoin      4% ( 6/145)     9% ( 6/64)   
MEAN±SD    
Age in years      56.1±14.4   52.1±14.0 
Hospitalization in years    13.5±15.1   7.1±11.1 
FTND (in smokers)      4.3±2.6 (N=92)  4.2±2.6 (N=43)d 
Daily number of cigarettes (in smokers)  25.5±11.4 (N=92)  23.6±11.0 (N=44) 
Chlorpromazine equivalentse   1897±1348   1246±1393   
Caffeine intake (mg/day)f   MEDIAN (25th P, 75th P)g   
All patientsh     130 (53, 265)   N=145  150 (9, 300) N=64 
Caffeine users     182 (107, 300) N=111i  219 (119, 362) N=48j 
♂ caffeine users    183 (110, 311) N=86  254 (126, 380) N=38 
♀ caffeine users    150 (72, 239)   N=25  160 (107, 300) N=10 
Smoking caffeine users   203 (113, 312) N=85  238 (135, 369) N=40 
   ♂ smoking caffeine users   203 (126, 329) N=74  283 (150, 406) N=31 
   ♀ smoking caffeine users   196 (107, 265) N=11  160 (107, 230) N=  9 
Non-smoking caffeine users   115 (53, 203)   N=26  150 (107, 289) N= 8 
   ♂ non-smoking caffeine users  115 (54, 157)   N=12  150 (107, 256) N= 7  
   ♀non-smoking caffeine users  128 (53, 238)   N=14  300      N=1 
Caffeine users: smoking and inducers  261 (149, 362) N=32  300 (160, 380) N=22 
   ♂ caffeine users: smoking and inducers 256 (145, 363) N=31  314 (176, 439) N=16 
   ♀ caffeine users: smoking and inducers 300                   N=1  160 (147, 314) N=  6 
Caffeine users: smoking or inducers  183 (107, 280) N=65  183 (109, 343) N=24 
   ♂ caffeine users: smoking or inducers 176 (107, 304) N=48  205 (119, 368) N=20 
   ♀ caffeine users: smoking or inducers 196 (99, 239)   N=17  128 (107, 262) N=4 
Caffeine users: no inducers   111 (53, 150)   N=14  128 (107)         N= 2 
   ♂ caffeine users: no inducers  115 (53, 150)   N=7  128 (107)         N= 2  
   ♀ caffeine users: no inducers  107 (53, 150)   N=7      
FTND: Fagerström Test for Nicotine Dependence. P: percentiles. SD: standard deviation. SMI: 
severe mental illness. 
aAll inpatients who had no schizophrenia (or schizoaffective disorder) were included in this group 
of other SMIs. Primary diagnoses were: 27% of patients (17/64) had severe personality disorders; 
17% (11/64) delusional disorders; 15% (10/64) substance use disorders; 14% (9/64) mood 
disorders; 14% (9/64) mental retardation; 10% (7/64) psychotic disorders not otherwise specified; 
and 2% (1/64)  obsessive-compulsive disorder.  
bAll current smokers were daily cigarette smokers; the lowest daily number of cigarettes was 5.   
None of the patients used other tobacco products. 
  
22 
 
cTaking inducers means taking omeprazole, carbamazepine or phenytoin.  
dOne patient did not cooperate in FTND scoring. 
eChlorpromazine equivalents were calculated by combining oral and long-acting antipsychotics 
(Baldessarini, 1985; Rey et al., 1985; Schulz et al, 1989; Mencias and Mayero, 2000; Woods, 
2003; and Kahn et al., 2008). 
fAverage weekly caffeine intake was determined by estimating caffeine content in caffeinated 
beverages in those patients who reported taking caffeine on a regular basis every week; then the 
weekly estimation was converted into mg/day. The standard caffeine content utilized was 100 
mg in a 150 cc cup of drip coffee; 45 mg in a cup of tea; and, for caffeinated sodas, 23 mg in a 
200 cc glass of soda (Gurpegui et al., 2004). In this hospital tea was not available. 
gDaily caffeine intake followed a non-normal distribution; thus, we described it using medians 
(and 25th and 75th percentiles).  
hDistorted by non-caffeine users. As smoking, taking inducers and gender may influence caffeine 
metabolism, medians after stratification are described to allow comparison with future published 
samples. 
iAmong 111 schizophrenia caffeine users, 91% (101/111) consumed coffee and 51% (57/111). 
consumed caffeinated colas.   
jAmong 48 non-schizophrenia caffeine users, 90% (43/48) consumed coffee and 44% (21/48) 
consumed caffeinated colas.  
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Table 2. Analysis of total daily caffeine intake (mg/day) in those consuming caffeine: significant variables in univariatea analyses, and in 
multivariate analyses using log-gamma regression.b             
   Bc 95% CI        p  Adjusted Bc 95% CI p  Effect sized   95% CI  
INPATIENTS WITH SCHIZOPHENIA (N=111) VS. THOSE WITH SMI (N=48)e 
Number of cigarettes 0.0208 (0.0121, 0.0294) <0.001   0.0218        (0.0135, 0.0230) <0.001  +2.20% (1.36, 3.05) 
Male sex  0.414    (0.078, 0.751) 0.02  --  --    --  --   -- 
Taking inducersf 0.316    (0.034, 0.598) 0.03     0.352           (0.106, 0.599)  0.005  +42.2% (11.1, 82.0)  
INPATIENTS WITH SCHIZOPHRENIA (N=111) VS. OUTPATIENTS WITH SCHIZOPHRENIAg (N=147)h 
Number of cigarettes 0.0203 (0.0136, 0.0270)      <0.001   0.0221        (0.0157, 0.0285)    <0.001  +2.24% (1.58, 2.89) 
Age >37 y  -- --     --  0.348        (0.125, 0.571)     0.002  +41.6% (13.3, 77.0) 
INPATIENTS WITH SCHIZOPHRENIA (N=111) VS. CONTROLS FROM GENERAL POPULATIONi (N=204)j 
Number of cigarettes 0.0263    (0.0201, 0.0325) <0.001  0.0263     (0.0201, 0.0325) <0.001  +2.66% (2.03, 3.30) 
Male sex  0.284      (0.0760, 0.492)  0.007     --      --     --  --   --  
College education –0.282    (–0.496, –0.069) 0.01  --      --     --  --   --  
Schizophrenia  0.528k    (0.325, 0.730) <0.001  --      --     --  -- -- 
Age >37 y  0.328      (0.116, 0.539)  0.002  --      --     --  --   --   
OUTPATIENTS WITH SCHIZOPHRENIA (N=147) VS. GENERAL POPULATION (N=204)l 
Number of cigarettes 0.0238   (0.0183, 0.0294) <0.001  0.0236      (0.0184, 0.0289) <0.001  +2.39% (1.86, 2.93)  
Male sex  0.290   (0.0616, 0.519) 0.01  --        --   --  --    -- 
College education –0.257   (‒0.495, ‒0.0192) 0.03  --        --   --  --    -- 
Schizophrenia  0.640m   (0.441, 0.839) <0.001  --        --   --  --    -- 
Age >37 y  0.277   (0.0528, 0.501) 0.02  0.253       (0.0733, 0.433) 0.006  +28.8% (7.6, 54.2)  
aThe independent variables used to build log-gamma regression models were number of cigarettes; male sex (1=male, 0=female); college 
education (1=having college education, 0 otherwise); schizophrenia (1=schizophrenia, 0 otherwise); age >37 years (1 if age >37 years, 0 
otherwise); history of alcohol abuse or dependence (1 if subject has history of alcohol abuse or dependence, 0 otherwise); and taking 
inducers (1 if taking carbamazepine, phenytoin or omeprazole, 0 otherwise).  Two variables, history of alcohol abuse and taking inducers, 
were not available in the outpatient schizophrenia and normal control samples from Gurpegui et al. (2006). 
bTotal caffeine intake in mg/day had a distribution that was right-skewed with a relatively heavy tail. Thus a log-gamma regression was 
appropriate. The log-gamma regression model with a log link that analyzed only caffeine users allowed including the fact that there were 
subjects with very high caffeine consumption relative to the rest of the subjects. In practice, in this study, a log-gamma regression model 
can be interpreted as the usual linear regression model with a log-transformed total caffeine intake as the dependent variable. However, the 
distribution of the errors is not the normal distribution but the gamma distribution, which is always right-skewed.   
cB=regression coefficient. 
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dAn adjusted effect size was computed as (exp(B)‒1) x 100. For the variable, number of cigarettes smoked, the effect size is 
interpreted as the percent increase in caffeine intake per one-cigarette increase in the number of cigarettes smoked.  For dichotomous 
independent variables, the effect size is interpreted as the percent increase in caffeine intake when comparing subjects with a value of 
1 versus subjects with a value of 0 in the independent variable. For instance, the effect size of taking inducers in the first 
panel,+42.2%, suggests that caffeine intake in subjects who were on inducers was 42.2% higher than that in subjects who were not on 
inducers. 
eAdjusted regression coefficients (B) and effect sizes were computed with the final log-gamma regression model which included 
number of cigarettes and taking inducers as independent variables. After controlling for potential confounders, there were no 
significant differences in total caffeine intake between schizophrenia inpatients who were caffeine consumers and inpatients with other 
severe mental illnesses who were caffeine consumers (p=0.6). 
fTaking omeprazole, carbamazepine or phenytoin.  
gThe schizophrenia outpatient age was 36.1±9.5 years; 78% (195/250) were males, and 10% (24/250) were college-educated. Most 
schizophrenia outpatients (81%, 203/250) had previously been hospitalized at least once. The mean ± standard deviation of number of 
hospitalizations was 4.1 ± 4.9. Most of the hospitalizations were short-term. In summary, these patients were clearly less chronic and 
less severely ill than the schizophrenia inpatients. 
hAdjusted regression coefficients (B) and effect sizes were computed with the final log-gamma regression model which included 
number of cigarettes and age >37 years as independent variables. After controlling for potential confounders, there were no significant 
differences in total caffeine intake between schizophrenia inpatients who were caffeine consumers and schizophrenia outpatients who 
were caffeine consumers (p=0.3). 
iThe controls’ mean age was 40.5±15.1 years; 39% (113 /290) were males and 49% (141/290) had a college education. 
jOnly the number of cigarettes smoked was found to have a significant effect on total daily caffeine intake in the multivariate log-
gamma regression model that included the other investigated independent variables and after a backward variable selection.  
kThe unadjusted effect size of schizophrenia on daily caffeine intake was +69.6% (38.4, 107.5). After adjusting for current smoking, 
the effect size continued to be significant and was +39.6% (14.5, 70.2), p=0.001. But after adjusting for the number of cigarettes 
instead of adjusting for current smoking, the effect size was lower and not significant, +20.1% (-1.6, 46.5), p=0.07. Thus, not only 
current smoking but heavy smoking accounts for the association between schizophrenia and caffeine consumption. 
lOnly the number of cigarettes smoked and age >37 years were found to have a significant effect on total daily caffeine intake in the 
multivariate log-gamma regression model that included the other investigated independent variables and after a backward variable 
selection.  
mThe unadjusted effect size of schizophrenia on daily caffeine intake was +89.7% (55.4, 131.4). After adjusting for both current 
smoking and age >37 years, the effect size continued to be significant and was +42.3% (15.6, 75.1), p=0.001. But after adjusting for 
both the number of cigarettes (instead of current smoking) and age >37 years, the effect size was lower and not significant, +16.2% (‒
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6.8, 44.9), p=0.2. Thus, not only current smoking but heavy smoking accounts for the association between schizophrenia and caffeine 
consumption. 
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Table 3. Caffeine intake: significant variables in the univariatea and multivariate analyses        
     OR 95% CI 2 p  Adjusted OR 95% CI Wald 2 p  
INPATIENTS WITH SCHIZOPHENIA (N=145) VS. THOSE WITH OTHER SEVERE MENTAL ILLNESSES (N=64)b 
Male sex    6.3 3.1-12.5 30.8 <0.001  3.61  1.7-7.9  10.6  0.001 
Current smoking   13.03  6.0-28.1 53.6 <0.001  8.81  3.9-20.3 26.4  <0.001 
Alcohol abuse/dependence (history) 4.1 1.5-11.0 9.0 0.003  --  --  --  --  
INPATIENTS WITH SCHIZOPHRENIA (N=145) VS. OUTPATIENTS WITH SCHIZOPHRENIA (N=250)c 
Male sex    3.01 1.9 4.8  22.5 <0.001  2.4  1.4    4.2 10.8  <0.001 
Current smoking   5.0 3.2-7.8  51.5 <0.001  4.8  2.9-7.8  37.8  <0.001 
Inpatient status    2.3 1.4-3.6  12.8 <0.001  3.5  2.0-5.9  20.6  <0.001 
INPATIENTS WITH SCHIZOPHRENIA (N=145) VS. CONTROLS FROM THE GENERAL POPULATION (N=290)d 
Male sex    2.5 1.6-3.9  17.0 <0.001  2.0  1.3-3.2  8.7  0.003 
Current smoking   3.4 2.1 5.4  26.8 <0.001  2.9  1.8- 4.7 18.2  .001 
College education   1.8 1.1 2.9  6.0 0.014  --  --  --  -- 
Age >37 y    0.49 0.31-0.78 9.2 0.002  --  --  --  --  
aIndependent variables for univariate analysis using cross tabulations with caffeine use or not as the dependent variable were 
schizophrenia illness, current daily smoking, history of alcohol abuse or dependence, sex, age >37 years, and college level of 
education (Gurpegui et al., 2006). 
bAdjusted ORs were computed with the final logistic regression model which included male sex and current smoking as independent 
variables (Hosmer-Lemeshow goodness-of-fit test 2=3.0; df=4; p=0.56). 
cAdjusted ORs were computed with the final logistic regression model which included male sex, current smoking and inpatient status 
as independent variables (Hosmer-Lemeshow goodness-of-fit test 2=5.22; df=4; p=0.27). 
dAdjusted ORs were computed with the final logistic regression model which included male sex and current smoking as independent 
variables (Hosmer-Lemeshow goodness-of-fit test 2=2.46; df=2; p=0.29). 
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Table 4. High caffeine intake in those consuming caffeine: significant variables in the univariatea and multivariate analyses    
     OR 95% CI 2 p  Adjusted OR 95% CI Wald 2 p  
INPATIENTS WITH SCHIZOPHENIA (N=111) VS. THOSE WITH OTHER SEVERE MENTAL ILLNESSES (N=48)b 
Current smoking   2.6  1.1-5.9  5.5 0.019  3.0  1.53-7.0 6.5  0.011  
Taking inducersc   2.3 1.2-4.3  6.6 0.01  2.6  1.3-5.0  7.7  0.005  
INPATIENTS WITH SCHIZOPHRENIA (N=111) VS. OUTPATIENTS WITH SCHIZOPHRENIA (N=147)d 
Current smoking    3.4 1.8-6.6  15.2 <0.001  3.4  1.8 -6.5 13.5  <0.001 
Inpatient status    0.46 0.28-0.76 9.2 0.002  0.47  0.28- 0.79 8.2  0.004 
College education   2.7 0.97-7.7  3.8 0.05  --  --  --  --   
INPATIENTS WITH SCHIZOPHRENIA (N=111) VS. CONTROLS FROM GENERAL POPULATION (N=204) 
Current smoking   3.08 1.9-5.0  22.1 <0.001  --  --  --  --  
aIndependent variables for univariate analysis using cross tabulations with high caffeine use or not within caffeine users as the 
dependent variable were schizophrenia illness, current daily smoking, history of alcohol abuse or dependence, gender, age >37 years, 
and college level of education (Gurpegui et al., 2006). Taking inducers was added as an independent variable in the first sample 
including schizophrenia and non-schizophrenia inpatients. 
bAdjusted ORs were computed with the final logistic regression model which included current smoking and taking inducers as 
independent variables (Hosmer-Lemeshow goodness-of-fit test 2=3.5; df=2; p=0.18). 
cTaking omeprazole, carbamazepine or phenytoin.  
dAdjusted ORs were computed with the final logistic regression model which included current smoking and inpatient status as 
independent variables (Hosmer-Lemeshow goodness-of-fit test 2= 0.29; df=2; p=0.87). 
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Table 5. Caffeinism (> 700 mg/day in patients induced by smoking or >350 mg/day in non-smokers)     
CASE DESCRIPTION 
Age Sex  Caffeine intake Diagnosis Smoking Taking  inducersa Alcohol abuse  Drug abuse 
(years)  (mg/d)    (cig/d)     /dependence /dependence     
SMOKING SCHIZOPHRENIA INPATIENTS (N=4) 
39 ♂ 1729   SCZ  40   20 mg/d omeprazole  Hx of abuse No Hx  
49 ♂ 1199    SCZ  40   20 mg/d omeprazole  Hx of abuse Hx of CAN abuse 
43 ♂  864    SCZ  40   No    No Hx  Hx of CAN & COC abuse 
52 ♂  856    SCZ  40   No    Hx of abuse No Hx      
SMOKING NON-SCHIZOPHRENIA INPATIENTS (N=1) 
41 ♂ 1499   PDNOS 40   20 mg/d omeprazole  No Hx   Hx of CAN, COC & HER abuse  
SMOKING SCHIZOPHRENIA OUTPATIENTS (N=7) 
52 ♂ 2200   SCZ  32       No current No current   
40 ♂ 1800   SCZ  20       No current No current   
41 ♂ 1400   SCZ  40       No current No current   
28 ♂ 1200   SCZ   60      Abuse  No current   
34 ♂ 1138   SCZ  60       No current No current   
44 ♂ 1000   SCZ  60       No current No current   
43 ♂ 1000   SCZ  30       Abuse  No current     
NON-SMOKING SCHIZOPHRENIA INPATIENTS (N=3 but 2 of 3 are explained by inducers) 
62 ♂ 599   SCZ  No Hx  40 mg/d omeprazole  No Hx  No Hx   - 
69 ♀ 525   SCZ  No Hx  40 mg/d omeprazole  No Hx  No Hx   - 
62 ♀ 450   SCZ  No Hx  No    No Hx  No Hx   -   
NON-SMOKING NON-SCHIZOPHRENIA INPATIENTS (N=1 but explained by inducers) 
58 ♂ 975   MR  No Hx  20 mg/d omeprazole  No Hx  No Hx   -   
NON-SMOKING SCHIZOPHRENIA OUTPATIENTS (N=2) 
51 ♀ 1000   SCZ  Hx       No current No current 
41 ♂ 423   SCZ  No Hx      No current No current     
FREQUENCIES OF CAFFEINISM > 700 mg/caffeine day in smokers 
    Whole sample  Using caffeine  Smokers using caffeine   
Schizophrenia inpatients 3% (4/145)  4% (4/111)  5% (4/85)     
Non-schizophrenia inpatients 2% (1/64)  2% (1/48)  3% (1/40)    
Schizophrenia outpatients 3% (7/250)  5% (7/147)  6% (7/120) 
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Spanish controls   0% (0/290)b  0% (0/204)  0% (0/78)       
CAN: cannabis; COC: cocaine; HER: heroin; Hx: history; MR: mental retardation; PDNOS: psychotic disorder NOS; SCZ: 
schizophrenia.  
aThe schizophrenia outpatient sample had no data on omeprazole intake. 
bThe definition of caffeinism as consuming >700 mg/day in smokers and >350 mg/day in non-smokers appears reasonable in our 
sample since no Spanish control met the criterion (highest daily intakes were 643 mg in smokers and 326 mg in non-smokers). 
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Table 6. Median intakes to explore access to tobacco and caffeine products in schizophrenia patients      
      Inpatients  Outpatients         
      Median (N)  Median (N)         
Number of daily cigarettes in smokers  20 (92)   30 (173) 
 
Caffeine in mg/day in caffeine users 
  Total sample    182.5 (111)  200 (147) 
 Smokers    203.1   (85)  238 (120) 
 Non-smokers    115      (26)  100   (27)         
